Immediate and long-term results of ATG induction therapy for delayed graft function compared to conventional therapy for immediate graft function

Transpl Int. 1999;12(1):2-9. doi: 10.1007/s001470050178.


The use of polyclonal antibodies for delayed graft function (DGF) was tested in 83 renal allograft recipients. Conventional immunosuppression (CI) was given to 52 patients with immediate graft function (IGF) while 31 patients with DGF received the polyclonal antibody ATG. Administration of OKT3 was restricted to steroid-resistant acute rejections in both groups. The incidence and severity of acute rejections, graft survival rate, CMV infections, and lymphocyte subsets were examined. ATG patients experienced a total of 0.6 acute rejections per patient, whereas CI patients had 0.9 on the average (P < 0.05). Second and third acute rejections occurred less frequently and later in the ATG group than in the CI group (P < 0.01). Steroid-resistant acute rejections occurred in 20 of the CI patients (38 %) but in only 7 of ATG patients (23 %). One-year graft survival in the CI and ATG groups was 98.1% and 93.2%, respectively. A decreased CD4 + to CD8 + T-lymphocyte ratio of about 0.5 was still detectable 5 years after the initial ATG administration. Hence, patients with DGF appear to benefit from induction therapy with ATG.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use*
  • Cytomegalovirus Infections / epidemiology
  • Graft Rejection / epidemiology
  • Graft Rejection / physiopathology
  • Graft Rejection / therapy
  • Graft Survival*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kidney Transplantation / immunology
  • Kidney Transplantation / physiology*
  • Lymphocyte Subsets / immunology
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Postoperative Complications


  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Muromonab-CD3